Clinical Trials
11 trialsNCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT05474690 2024-02-26
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
Henan Cancer Hospital
Phase 3 Withdrawn
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04762901 2022-04-26
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
Wake Forest University Health Sciences
Phase 1 Withdrawn
NCT03872505 2021-08-25
PANDoRA
Cedars-Sinai Medical Center
Phase 2 Withdrawn
NCT03058939 2019-04-22
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Withdrawn
NCT00006123 2018-05-16
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Withdrawn
NCT03032614 2017-10-10
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT00397501 2017-04-21
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
OHSU Knight Cancer Institute
Phase 1/2 Withdrawn
NCT02102438 2016-08-31
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
Instituto do Cancer do Estado de São Paulo
Phase NA Withdrawn
NCT02396433 2015-08-25
Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers
The University of Texas Health Science Center at San Antonio
Phase 1/2 Withdrawn